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BRIEF COMMUNICATION
Age and Acute Ischemic Stroke Outcome in 
North American Patients With COVID- 19
Adam A. Dmytriw , MD, MPH, MSc; Mahmoud Dibas, MD; Clemens M. Schirmer , MD, PhD;  
Fabio Settecase, MD, MSc; Manraj K. S. Heran, MD; Aslan Efendizade , DO; Anna Luisa Kühn , MD, PhD; 
Ajit S. Puri, MD; Johanna Ospel , MD; Bijoy Menon , MD; Sanjeev Sivakumar, MD; Ashkan Mowla, MD; 
Daniel Vela- Duarte, MD; Italo Linfante, MD; Guilherme Dabus , MD; Robert W. Regenhardt , MD, PhD; 
Aman B. Patel, MD; Thabele Leslie- Mazwi , MD; Salvatore D’Amato, MD; Joseph Rosenthal, MD; Alicia Zha , MD; 
Nafee Talukder, MD; Sunil Sheth , MD; Daniel Cooke, MD; Lester Y. Leung, MD, MSc; Adel Malek, MD, PhD; 
Barbara Voetsch, MD, PhD; Siddharth Sehgal, MD; Ajay K. Wakhloo , MD, PhD; Hannah Wu, MD;  
Jake Cohen , MD; David Turkel- Parella, MD; Andrew Xavier, MD; Ambooj Tiwari , MD, MPH; on behalf of 
the North American Neurovascular COVID- 19 (NAN- C) Consortium
BACKGROUND: Acute ischemic stroke (AIS) in the context of COVID- 19 has received considerable attention for its propensity 
to affect patients of all ages. We aimed to evaluate the effect of age on functional outcome and mortality following an acute 
ischemic event.
METHODS AND RESULTS: A prospectively maintained database from comprehensive stroke centers in Canada and the United 
States was analyzed for patients with AIS from March 14 to September 30, 2020 who tested positive for SARS- CoV- 2. The 
primary outcome was Modified Rankin Scale score at discharge, and the secondary outcome was mortality. Baseline charac-
teristics, laboratory values, imaging, and thrombectomy workflow process times were assessed. Among all 126 patients with 
COVID- 19 who were diagnosed with AIS, the median age was 63 years (range, 27– 94). There were 35 (27.8%) patients with AIS 
in the aged ≤55 years group, 47 (37.3%) in the aged 56 to 70 group, and 44 (34.9%) in the aged >70 group. Intravenous tissue 
plasminogen activator and thrombectomy rates were comparable across these groups, (P=0.331 and 0.212, respectively). 
There was a significantly lower rate of mortality between each group favoring younger age (21.9% versus 45.0% versus 48.8%, 
P=0.047). After multivariable adjustment for possible confounders, a 1- year increase in age was significantly associated with 
fewer instances of a favorable outcome of Modified Rankin Scale 0 to 2 (odds ratio [OR], 0.95; 95 CI%, 0.90– 0.99; P=0.048) 
and higher mortality (OR, 1.06; 95 CI%, 1.02– 1.10; P=0.007).
CONCLUSIONS: AIS in the context of COVID- 19 affects young patients at much greater rates than pre- pandemic controls. 
Nevertheless, instances of poor functional outcome and mortality are closely tied to increasing age.
Key Words: acute ischemic stroke ■ age outcomes ■ COVID- 19 pandemic ■ SARS- CoV- 2
The COVID- 19 epidemic emerged in Wuhan, China in December 2019, and was associated with an unpreceded healthcare crisis.1,2 The 
intersection of acute ischemic stroke and COVID- 
19‒ related disease represents a public health crisis 
that requires urgent communication to the medical 
community.3,4 AIS in those without traditional risk 
factors is an emerging hallmark of COVID- 19, un-
precedented in the modern era of previous viral 
pandemics, and a distinguishing characteristic com-
pared with other coronavirus infections. Of late, con-
cerns have been raised about acute ischemic stroke 
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(AIS) secondary to large vessel occlusions in young 
patients with COVID- 19.5,6 We sought to analyze the 
clinical outcomes of AIS in patients positive with 
COVID- 19 based on age.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon rea-
sonable request. We studied all 126 patients with 
AIS who tested positive for SARS- CoV- 2 and were 
admitted to 19 stroke centers in the United States 
and Canada, from March 14 to September 30, 2020. 
We stratified age into 3 prespecified groups (≤55, 
56– 70, and >70 years). Continuous variables were 
presented as median (interquartile range) and com-
pared by Kruskal‒ Wallis test. Categorical variables 
were compared by the Pearson Chi- Square test. 
The impact of age on clinical outcomes of Modified 
Rankin Scale and mortality was investigated using 
univariable and multivariable logistic regression anal-
yses. Covariates found to be significant upon univar-
iable analysis (P≤0.05) were included with age (once 
as a continuous variable and again as a categori-
cal variable) in the multivariable models. All analy-
ses were performed using R software version 4.0.2. 
Institutional review board approval was obtained at 
all institutions, with consent waived per usual retro-
spective protocol.
RESULTS
The median age of the included patients was 63 years 
(range, 27– 94). There were 35 (27.8%) patients with 
AIS in the aged ≤55 years group, 47 (37.3%) in the 
56 to 70 group, and 44 (34.9%) in the >70 group. 
Almost one third (38%) of the sample were aware 
of COVID- 19 diagnosis before stroke admission. 
We found significant differences between the 3 age 
groups on sex, atrial fibrillation, prior anticoagula-
tion, coronary artery disease, hypertension, and 
hyperlipidemia (Table 1). The middle cerebral artery 
was the most commonly occluded vessel (63.0%) 
followed by the internal carotid artery (24.7%), ver-
tebrobasilar segment (17.3%), and anterior cerebral 
artery (4.94%). National Institutes of Health Stroke 
Scale score was not significantly different between 
the 3 groups (median, 15.0 versus 11.0 versus 12.00; 
P=0.174). There was no difference in large vessel 
occlusion rates among the groups (47.1% versus 
46.5% versus 43.9%, P=0.956). All hematologic and 
laboratory parameters were similar between the age 
groups except for triglycerides which were greater in 
the aged ≤55 years group who suffered strokes (me-
dian mg/dL, 152 versus 149 versus 115; P=0.031). 
Intravenous tissue plasminogen activator was given 
to 32.4%, 22.2%, and 18.2% of the age groups ≤55, 
56 to 70, and >70 years, respectively (P=0.331). 
Similarly, there was no difference in thrombectomy 
rates between the age groups (33.3% versus 16.3% 
Table 2. Outcomes of the Included Patients Stratified to Age Groups
N* ≤55 (n=35) 56– 70 (n=47) >70 (n=44) Total (n=126) P Value
Post procedure mTICI 28
0 1 (9.1%) 0 (0%) 0 (0%) 1 (3.6%)
2 0 (0%) 1 (14.3%) 0 (0%) 1 (3.6%)
2a 2 (18.2%) 2 (28.6%) 1 (10.0%) 5 (17.9%)
2b 7 (63.6%) 0 (0%) 2 (20.0%) 9 (32.1%)
3 1 (9.1%) 4 (57.1%) 7 (70.0%) 12 (42.9%)
Discharge mRS 110
0 4 (13.3%) 3 (7.69%) 1 (2.44%) 8 (7.27%) 0.222
1 5 (16.7%) 2 (5.13%) 2 (4.88%) 9 (8.18%)
2 1 (3.33%) 3 (7.69%) 3 (7.32%) 7 (6.36%)
3 8 (26.7%) 3 (7.69%) 6 (14.6%) 17 (15.5%)
4 4 (13.3%) 6 (15.4%) 6 (14.6%) 16 (14.5%)
5 1 (3.33%) 4 (10.3%) 3 (7.32%) 8 (7.27%)
6 7 (23.3%) 18 (46.2%) 20 (48.8%) 45 (40.9%)
Discharge mRS 110
0– 2 10 (33.3%) 8 (20.5%) 6 (14.6%) 24 (21.8%) 0.118
3– 6 20 (66.7%) 31 (79.5%) 35 (85.4%) 86 (78.2%)
sICH 116 4 (12.1%) 4 (9.30%) 1 (2.50%) 9 (7.76%) 0.277
Mortality 113 7 (21.9%) 18 (45.0%) 20 (48.8%) 45 (39.8%) 0.047
mRS indicates Modified Rankin Scale; mTICI, modified treatment in cerebral infarction; and sICH, symptomatic intracranial haemorrhage.
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versus 23.8%, P=0.212). Rates of favorable out-
comes (Modified Rankin Scale ≤2) at discharge were 
not significantly different between the groups (33.3% 
versus 20.5% versus 14.6%, P=0.118). There was a 
significantly lower rate of mortality between each age 
group favoring younger age (21.9% versus 45.0% 
versus 48.8%, P=0.047).
After adjusting for hypertension and National 
Institutes of Health Stroke Scale in the multivariable 
model (Tables 2 and 3), a 1- year increase in age was 
significantly associated with fewer instances of favor-
able outcome (odds ratio [OR], 0.95; 95% CI, 0.90– 0.99; 
P=0.048). Furthermore, on mortality modeling and after 
adjusting for diabetes mellitus and National Institutes 
of Health Stroke Scale (Table S1), we observed signifi-
cantly higher rates of mortality with each 1- year increase 
in age (OR, 1.06; 95% CI, 1.02– 1.10; P=0.007).
DISCUSSION
AIS is known historically to be a disease of older pa-
tients, and our results suggest that patients still fare 
poorly as age increases in the context of COVID- 19. 
Recently, it has been shown that patients with AIS in-
fected with COVID- 19 were more likely to be younger 
and have higher rates of large vessel occlusions com-
pared with historical controls.7 Similarly, in this study, 
there were 35 patients (27.8%) aged <56 years. As a 
virus which targets angiotensin- converting enzyme 2 
receptors, it’s suggested that direct endothelial damage 
may be at least partly to blame for the unprecedented 
burden upon the young and those without traditional 
risk factors.8 AIS is known historically to be a disease of 
older patients, and our results suggest that patients still 
fare poorly as age increases in the context of COVID- 19.
It is still uncertain what the exact mechanisms are 
that predispose this population to AIS, however, we 
corroborate early observations of better outcomes and 
lower rates of mortality in younger patients.9 There are 
2 major age- related discoveries that differentiate these 
findings from pre- COVID era AIS. The first is that the 
proportion of young patients experiencing AIS and 
particularly large vessel occlusions is vastly more than 
that before the pandemic. This is a crucial finding, and 
likely relates to hypercoagulability in the absence of tra-
ditional risk factors. Not only does this imply different 
pathophysiology in these patients, but seemingly also 
from other coronavirus pandemics.
The other surprising difference is that the risk of poor 
outcomes increases with every year of age. We believe 
this is crucial information to disseminate as although at-
tention to the young is important, there is potential to 
ignore the fact that older patients fare worse to a degree 
at this also not precedented before the pandemic. In 
this case, there is reason to believe that there is an inter-
action between COVID- associated stroke, respiratory 
disease, and age. These associations with age merit 
further study.
This is a large study that was conducted through 
several centers in North America. Despite that, this 
study has some limitations. Principally, some vari-
ables that might affect the outcomes including so-
cioeconomic status, local healthcare infrastructure, 
resources, and personal social support networks may 
also be at play. Furthermore, this study was done in 
healthcare centers and thus these patients have more 
Table 3. Multivariable Binary Logistic Regression Models to Test for the Impact of Age on the Outcomes in Patients With 
Acute Ischemic Stroke Infected With COVID- 19
Outcome Variables
Multivariable Logistic Regression
OR (95 CI%, P Value)
mRS 0– 2 Model 1 Age (1 y increase) 0.95 (0.90– 0.99, P=0.048)
Hypertension 0.23 (0.04– 1.19, P=0.092)
Admission NIHSS score 0.74 (0.61– 0.84, P<0.001)
Model 2 Age, y (56– 70 vs ≤55) 0.35 (0.05– 2.06, P=0.257)
Age, y (>70 vs ≤55) 0.20 (0.03– 1.20, P=0.090)
Hypertension 0.23 (0.04– 1.16, P=0.086)
Admission NIHSS score 0.76 (0.64– 0.85, P<0.001)
Mortality Model 1 Age (1 y increase) 1.06 (1.02– 1.10, P=0.007)
Diabetes mellitus 4.38 (1.65– 12.29, P=0.004)
Admission NIHSS score 1.09 (1.04– 1.16, P=0.001)
Model 2 Age, y (56– 70 vs ≤55) 2.26 (0.65– 8.44, P=0.208)
Age, y (>70 vs ≤55) 4.76 (1.28– 20.15, P=0.025)
Diabetes mellitus 4.14 (1.58– 11.42, P=0.005)
Admission NIHSS score 1.09 (1.03– 1.15, P=0.002)
All variables that had a P≤0.05 in the univariate model in Table S1 were included with age in the multivariable model. mRS indicates Modified Rankin Scale; 
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severe COVID- 19 infections, which limits the generaliz-
ability to the whole population.
CONCLUSIONS
In North America, acute ischemic stroke in the context 
of COVID- 19 is observed to affect young patients at 
much greater rates than pre- pandemic control peri-
ods. Importantly however, instances of poor functional 
outcome and mortality are closely tied to increasing 
age. Interactions between age, respiratory disease, 
and AIS may be important in COVID- 19.
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Table S1. Univariable binary logistic regression analysis showing associations with Modified Rankin Scale 
(mRS) 0-2 and mortality. 
  Univariate analysis -- mRS 0-2 Univariate analysis -- mortality 
Variables OR (95 CI%, P-value) 
Age (one year increase) 0.97 (0.93-0.99, p=0.036) 1.03 (1.01-1.06, p=0.028) 
Age (56 - 70 vs ≤ 55) 0.43 (0.13-1.30, p=0.139) 2.92 (1.06-8.74, p=0.044) 
Age (> 70 vs ≤ 55) 0.33 (0.10-1.01, p=0.057) 3.40 (1.25-10.13, p=0.021) 
Sex (Male vs female) 1.07 (0.42-2.71, p=0.893) 1.41 (0.66-3.02, p=0.377) 
Race (Caucasian vs Black) 1.48 (0.50-4.55, p=0.483) 0.45 (0.17-1.12, p=0.091) 
Race (Others vs Black) 0.92 (0.25-3.25, p=0.901) 1.30 (0.51-3.37, p=0.580) 
Smoking 0.81 (0.17-2.85, p=0.758) 2.17 (0.75-6.37, p=0.149) 
Atrial fibrillation 2.37 (0.73-7.20, p=0.132) 1.07 (0.36-3.03, p=0.902) 
Prior anticoagulation 1.41 (0.36-4.70, p=0.589) 1.32 (0.43-4.00, p=0.615) 
Coronary artery disease 1.52 (0.44-4.62, p=0.479) 0.52 (0.16-1.50, p=0.247) 
Congestive heart failure 1.73 (0.43-5.99, p=0.405) 0.87 (0.25-2.80, p=0.812) 
Diabetes mellitus 0.40 (0.13-1.06, p=0.078) 3.71 (1.69-8.41, p=0.001) 
Hypertension 0.35 (0.13-0.94, p=0.034) 1.36 (0.57-3.37, p=0.496) 
Hyperlipidemia 0.90 (0.35-2.34, p=0.835) 1.09 (0.50-2.39, p=0.829) 
 Previous stroke 2.42 (0.88-6.58, p=0.082) 1.67 (0.69-4.04, p=0.257) 
Chronic kidney disease 1.37 (0.44-3.91, p=0.570) 0.60 (0.21-1.54, p=0.300) 
Admission NIHSS score 0.78 (0.68-0.87, p<0.001) 1.08 (1.03-1.13, p=0.001) 
ASPECTS (6-10 vs 5-0) 3.55 (0.61-67.62, p=0.245) 0.34 (0.10-1.05, p=0.063) 
IV tPA 1.19 (0.41-3.21, p=0.733) 0.62 (0.24-1.50, p=0.302) 
High dose enoxaparin 2.56 (0.29-22.88, p=0.367) 0.51 (0.03-3.75, p=0.561) 
Thrombectomy 0.38 (0.08-1.25, p=0.145) 1.08 (0.42-2.66, p=0.873) 
NIHSS: National Institutes of Health Stroke Scale; ASPECTS: The Alberta Stroke Program Early CT Score; IV 
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